Catal­ent’s Covid-19 vac­cine man­u­fac­tur­ing site hit with Form 483 over for­eign ob­jects in vials and oth­er QC is­sues

An In­di­ana-based Catal­ent fa­cil­i­ty that pro­duces Covid-19 vac­cines is fac­ing scruti­ny from the FDA over an in­spec­tion last month.

Catal­ent’s plant in Bloom­ing­ton, IN, which han­dles fill and fin­ish op­er­a­tions as well as com­mer­cial scale bio­man­u­fac­tur­ing, was hit with a 19-page Form 483 from the FDA. The in­spec­tion re­port­ed a to­tal of 12 ma­jor ob­ser­va­tions made when the fa­cil­i­ty was in­spect­ed be­tween Aug. 1 and Sept. 1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER